Vyne Therapeutics Announces Covered Status for Zilxi with Express Scripts

Zilxi is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide.

Vyne Therapeutics Inc.’s Zilxi (minocycline) will be covered on Express Scripts' National Preferred, Flex, and Basic commercial formularies effective October 2, 2020.

Zilxi is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide.

"The addition of Express Scripts to our national coverage for Zilxi is a significant milestone as it represents a large portion of the U.S. commercial coverage patient population," says David Domzalski, Chief Executive Officer of Vyne, in a news release. "We are pleased that our contract provides access to this important new option for physicians and patients who have not previously had the rosacea treatment outcomes they are seeking." 

The annual list price of Zilxi is $485 per 30-gram canister.  Zilxi was approved by the U.S. Food and Drug Administration in May 2020.